Latest Anakinra Stories
- HS is a painful, chronic inflammatory skin disease that impacts approximately 1 percent of the adult population worldwide with no approved treatment options available,, AMSTERDAM,
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark,
Achieve is conducting a multicenter, randomized, single-dose study assessing the pharmacodynamic parameters of an experimental combination therapy in
NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S.
- The long-term safety profile was consistent with pivotal trials of Cimzia® ATLANTA, May 5, 2014 /PRNewswire/ -- UCB announced today results from the PRECiSE 3 7-year open label extension
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.